公开(公告)号：WO2017221076A1

公开(公告)日：2017-12-28

申请号：PCT/IB2017/000965

申请日：2017-06-23

Applicant: INSTITUT PASTEUR ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  MINISTÈRE DES ARMÉES - DIRECTION CENTRALE DU SERVICE DE SANTÉ DES ARMÉES

Inventor： TANGY, Frédéric ,  KOMAROVA, Anastassia ,  MURA, Marie ,  COMBREDET, Chantal

IPC: A61K39/12 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K39/015 ,  A61K39/39 ,  A61K2039/51 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/555 ,  A61K2039/55588 ,  A61K2039/70 ,  A61P31/00 ,  A61P33/00 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2760/18434 ,  C12N2760/18443 ,  C12N2760/18444 ,  C12N2770/36134 ,  Y02A50/383 ,  Y02A50/394 ,  Y02A50/412

Abstract: The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5' copy-back DI- RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV ( wt - MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5' copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

Abstract translation: 本发明属于预防或治疗疾病，特别是感染性疾病领域，更具体地涉及多价疫苗领域。 本发明人描述了由重组MV菌株（包括基于rMV的疫苗和野生型MV（wt-MV））产生的5'拷贝回DI-RNA。 比较这些DI-RNA产生在不同细胞类型中的效率。 首次对特异性结合RIG-I，MDA5和LGP2的5'拷贝返回DI-RNA进行评估，并将其与I型IFN信号传导中的功能结果相关联。 发明人提供了产品组合物，其至少包含（i）编码至少一种抗原的拯救的重组MV源性病毒的颗粒的混合物，（ii）包含至少一种抗原的重组和/或纯化的蛋白质。 不管产品的介绍如何，特别是不管产品是分离的还是容易分离的或者以混合物的形式呈现的。

公开(公告)号：WO2015134606A1

公开(公告)日：2015-09-11

申请号：PCT/US2015/018728

申请日：2015-03-04

Applicant: ORBIS HEALTH SOLUTIONS LLC

Inventor： WAGNER, Thomas, E.

IPC: A61K9/00 ,  C12N1/16 ,  C12N1/00 ,  A61K45/00

CPC classification number: A61K9/5068 ,  A61K9/19 ,  A61K31/70 ,  A61K31/7088 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/5154 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/55588 ,  A61K2039/60 ,  C12N1/16

Abstract: The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.

Abstract translation: 本发明一般涉及用于递送疫苗的组合物和方法。 本文公开的组合物和方法特别可用于制备预防和治疗疫苗。

公开(公告)号：WO2015061416A2

公开(公告)日：2015-04-30

申请号：PCT/US2014/061723

申请日：2014-10-22

Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： SCHLOM, Jeffrey ,  TSANG, Kwong-Yok

IPC: A61K38/08

CPC classification number: C07K14/4727 ,  A61K31/00 ,  A61K38/00 ,  A61K38/191 ,  A61K38/193 ,  A61K38/195 ,  A61K38/20 ,  A61K38/217 ,  A61K38/22 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55588 ,  C07K14/82 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/24143 ,  C12N2710/24171 ,  A61K2300/00

Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

Abstract translation: 本发明提供了来自粘蛋白1（MUC1-C）的C末端亚基的人细胞毒性T淋巴细胞（CTL）激动剂表位，其可以用作肽，多肽（蛋白质）和 或用于预防或治疗癌症的疫苗或其他组合物中。 本发明还提供了编码肽，蛋白质或多肽的核酸，包含该核酸的载体，包含该肽，多肽，核酸或载体的细胞及其组合物。

公开(公告)号：WO2014139672A1

公开(公告)日：2014-09-18

申请号：PCT/EP2014/000650

申请日：2014-03-11

Applicant: ICON GENETICS GMBH ,  UNIVERSITY OF SOUTHAMPTON

Inventor： SAVELYEVA, Natalia ,  JARCZOWSKI, Franziska ,  KANDZIA, Romy ,  NICKSTADT, Anja ,  THIEME, Frank ,  KLIMYUK, Victor ,  GLEBA, Yuri ,  BUI-MINH, Duc ,  STEVENSON, Freda K. ,  CHOTPRAKAIKIAT, Warayut

IPC: A61K39/00 ,  C07K14/71 ,  A61K39/39

CPC classification number: A61K39/0011 ,  A61K47/646 ,  A61K2039/55588 ,  A61K2039/6037 ,  C12N9/12 ,  C12Y207/10001

Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.

Abstract translation: 包含用于产生针对HER2 / neu蛋白的免疫应答的蛋白质抗原的蛋白质缀合物和与所述蛋白质抗原共价结合的免疫原性载体，其中所述蛋白质抗原（i）具有氨基酸的300个或更多个连续氨基酸的序列片段 SEQ ID NO：1的序列; 或（ii）具有300个或更多个氨基酸残基的变体序列片段，其中所述变体序列片段的氨基酸序列与SEQ ID：1的序列部分具有至少85％的序列同一性; 或（iii）具有300个或更多个氨基酸残基的变体序列片段，并且与所述变体序列片段中的氨基酸序列的300个或更多个氨基酸残基的序列片段相比，具有1至10个取代，缺失或添加 SEQ ID NO：1或2。

公开(公告)号：WO2014095943A1

公开(公告)日：2014-06-26

申请号：PCT/EP2013/077006

申请日：2013-12-17

Applicant: EUROCINE VACCINES AB

Inventor： ARWIDSSON, Hans ,  MALTAIS, Anna-Karin

IPC: A61K39/145 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/543 ,  A61K2039/55511 ,  A61K2039/55588 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16134 ,  Y02A50/388 ,  Y02A50/466

Abstract: The invention relates to nasally-administered vaccine compositions effective in naive subjects such as children. Further, the vaccine composition is suitable for vaccinating the general population during a pandemic. One aspect of the invention is directed to the paediatric use of the vaccine of the invention including a vaccine effective in children against seasonal influenza virus strains. A further aspect of the invention is directed to subjects of all age groups when the composition is for pandemic use.

Abstract translation: 本发明涉及在天真受试者例如儿童中有效的经鼻施用的疫苗组合物。 此外，疫苗组合物适合在大流行期间接种普通人群。 本发明的一个方面涉及本发明的疫苗的儿科用途，其包括针对季节性流感病毒株的儿童有效的疫苗。 本发明的另一方面涉及当组合物用于大流行性使用时所有年龄组的受试者。

公开(公告)号：WO2013006842A2

公开(公告)日：2013-01-10

申请号：PCT/US2012/045854

申请日：2012-07-06

Applicant: NOVARTIS AG ,  GEALL, Andrew

Inventor： GEALL, Andrew

IPC: A61K39/12 ,  A61K39/295 ,  A61P31/00 ,  A61P11/00

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/55588 ,  C12N2710/16134 ,  C12N2760/18534 ,  C12N2770/36143

Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms - a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form - are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA- based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.

Abstract translation: 本发明一般涉及包含RNA组分和多肽组分的免疫原性组合物。 以两种不同形式递送抗原表位的免疫原性组合物 - 来自病原体的第一个表位，以RNA编码的形式; 并且来自相同病原体的多肽形式的第二表位有效诱导对病原体的免疫应答。 本发明还涉及包含基于RNA的引发组合物和基于多肽的增强组合物的试剂盒。 该试剂盒可以用于顺序施用引发剂和促进组合物。

公开(公告)号：WO2012109404A1

公开(公告)日：2012-08-16

申请号：PCT/US2012/024409

申请日：2012-02-09

Applicant: GLOBEIMMUNE, INC. ,  APELIAN, David ,  KING, Thomas, H. ,  GUO, Zhimin ,  COESHOTT, Claire

Inventor： APELIAN, David ,  KING, Thomas, H. ,  GUO, Zhimin ,  COESHOTT, Claire

IPC: A61K39/29 ,  A61K36/06 ,  C07K14/02

CPC classification number: A61K39/292 ,  A61K31/675 ,  A61K36/06 ,  A61K36/12 ,  A61K39/12 ,  A61K39/29 ,  A61K45/06 ,  A61K47/46 ,  A61K2039/51 ,  A61K2039/5158 ,  A61K2039/521 ,  A61K2039/523 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55516 ,  A61K2039/55588 ,  A61K2039/6006 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/02 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/00022 ,  C12N2710/00034 ,  C12N2730/10122 ,  C12N2730/10134

Abstract: Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.

Abstract translation: 公开了用于治疗和/或预防HBV感染及其症状的基于酵母的免疫治疗组合物，乙型肝炎病毒（HBV）抗原和融合蛋白，以及使用基于酵母的免疫治疗组合物，HBV抗原和 用于预防和/或治疗HBV和/或其症状的融合蛋白。

公开(公告)号：WO2010128524A8

公开(公告)日：2011-11-24

申请号：PCT/IN2010000287

申请日：2010-05-03

Applicant: CADILA HEALTHCARE LTD ,  GLUECK REINHARD ,  FAZIO AGATA ,  GIANINO VIVIANA ,  BILLETER MARTIN

Inventor： GLUECK REINHARD ,  FAZIO AGATA ,  GIANINO VIVIANA ,  BILLETER MARTIN

IPC: A61K35/76 ,  A61K38/15 ,  A61K39/165 ,  A61K39/295 ,  A61P33/06 ,  C12N7/01 ,  C12N7/02 ,  C12N7/04 ,  C12N7/08 ,  C12N15/09

CPC classification number: A61K39/165 ,  A61K35/13 ,  A61K38/2013 ,  A61K39/0015 ,  A61K39/015 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/575 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/18421 ,  C12N2760/18434 ,  C12N2760/18442 ,  C12N2760/18443

Abstract: The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-I) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen 1 (AMAl) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently. In a preferred embodiment, the CS, the MSPl and the AMAl proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans; the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the recombinant vaccine in the prophylactic treatment of malaria.

Abstract translation: 本发明涉及含有不同减毒重组麻疹 - 疟疾载体的麻疹 - 疟疾联合疫苗，其包含编码恶性疟原虫抗原的异源核酸。 优选地，它涉及病毒载体，其包含编码恶性疟原虫的环子孢子（CS）蛋白，恶性疟原虫的裂殖子表面蛋白1（MSP-1）及其衍生物（p-42; p-83- 30-38）以其糖基化和分泌形式，以及恶性疟原虫的顶膜抗原1（AMA1），以其锚定或分泌形式存在。 该病毒载体来源于减毒麻疹病毒，其基于用作疫苗并有效递送感兴趣基因并且有效结合并感染相关免疫细胞的菌株。 在一个优选的实施方案中，CS，MSP1和AMA1蛋白由病毒产生，从而它们会在哺乳动物，优选人类中产生有效的免疫应答; 由于人类密码子优化，蛋白质的表达升高。 此外，本发明涉及该重组疫苗在预防性治疗疟疾中的用途。

公开(公告)号：WO2010037513A1

公开(公告)日：2010-04-08

申请号：PCT/EP2009/006979

申请日：2009-09-28

Applicant: IMMATICS BIOTECHNOLOGIES GMBH ,  SCHOOR, Oliver ,  HILF, Norbert ,  WEINSCHENK, Toni ,  TRAUTWEIN, Claudia ,  WALTER, Steffen ,  SINGH, Harpreet

Inventor： SCHOOR, Oliver ,  HILF, Norbert ,  WEINSCHENK, Toni ,  TRAUTWEIN, Claudia ,  WALTER, Steffen ,  SINGH, Harpreet

IPC: A61K39/00 ,  A61P35/00 ,  A61K38/08 ,  A61K38/16

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/06 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.

Abstract translation: 本发明涉及免疫治疗肽及其在​​免疫治疗中的用途，特别是癌症的免疫治疗。 本发明公开了肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 特别地，本发明的肽的组合物可用于引发针对胶质瘤的抗肿瘤免疫应答的疫苗组合物中。

公开(公告)号：WO2009069130A3

公开(公告)日：2009-07-16

申请号：PCT/IL2008001551

申请日：2008-11-27

Applicant: UNIV RAMOT ,  HOCHMAN NIRA ,  HOCHMAN JACOB ,  WEISS ERVIN ,  OFEK ITZHAK

Inventor： HOCHMAN NIRA ,  HOCHMAN JACOB ,  WEISS ERVIN ,  OFEK ITZHAK

IPC: A61K39/39 ,  A61K36/45

CPC classification number: A61K39/39 ,  A61K35/768 ,  A61K36/45 ,  A61K39/0011 ,  A61K39/0258 ,  A61K39/092 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/55511 ,  A61K2039/55588 ,  A61K2039/70 ,  C12N2740/12034

Abstract: The subject invention provides new adjuvant therapy.

Abstract translation: 本发明提供了新的辅助治疗。